Key Finding
Electroacupuncture reversed neuropathic pain by upregulating astrocytic glutamate transporters GLAST and GLT-1, thereby reducing spinal glutamate levels, an effect that was abolished when these transporters were pharmacologically blocked.
Researchers in China investigated how electroacupuncture (EA) might relieve chronic nerve pain by studying its effects on brain support cells called astrocytes. Using rats with surgically-induced nerve injury, they compared untreated animals to those receiving electroacupuncture at two commonly used points (ST36 and GB34) on both legs. The study involved 69 rats divided into normal, injured-untreated, and injured-with-EA groups.
The researchers found that nerve injury decreased pain thresholds and disrupted the normal balance of brain chemicals, specifically increasing glutamate, a substance that can amplify pain signals. Electroacupuncture treatment reversed these changes by increasing the expression of two important proteins (GLAST and GLT-1) in astrocytes that help remove excess glutamate from the nervous system. When the research team blocked these proteins with special antagonists, electroacupuncture lost its pain-relieving effects, confirming their importance.
What this means for patients: This study helps explain one biological mechanism behind acupuncture's pain-relieving effects. Electroacupuncture appears to work partly by helping support cells in the nervous system better regulate glutamate, a chemical messenger involved in pain transmission. By reducing glutamate levels through improved cellular cleanup processes, electroacupuncture may decrease chronic pain signals. This research adds to growing evidence that acupuncture produces measurable biological changes rather than just placebo effects, particularly for chronic nerve pain conditions like sciatica, diabetic neuropathy, or post-surgical pain. If you're considering acupuncture for chronic pain, seek treatment from a licensed acupuncturist with experience in treating neuropathic pain conditions.
This rat model study (n=69) investigated EA's analgesic mechanisms in chronic constriction injury (CCI)-induced neuropathic pain, focusing on astroglial glutamate regulation. EA was administered bilaterally at ST36 and GB34. Results demonstrated that CCI decreased pain thresholds, reduced GLAST expression, and elevated spinal glutamate levels. EA treatment significantly reversed these pathological changes, upregulating GLAST and GLT-1 expression in astrocytes and reducing glutamate concentrations. Validation studies (n=30) using intrathecal GLAST/GLT-1 antagonists abolished EA's analgesic effects, confirming the mechanistic pathway. Western blot, PCR, immunofluorescence, and HPLC methodologies confirmed protein expression and neurotransmitter levels. Clinical relevance: EA's cumulative analgesic effect in neuropathic pain appears mediated through enhanced astroglial glutamate-glutamine cycling, specifically via upregulation of glutamate transporters. This provides mechanistic support for EA protocols in chronic neuropathic conditions and suggests the glutamate-glutamine cycle as a therapeutic target. Bilateral lower limb point selection proved effective in this spinal pain model.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 A 6-week integrative Korean medicine treatment centered on high-dose Angelica gigas produced clinically significant improvements in pain, function, and quality of life in a patient with 10-year treatment-refractory fibromyalgia unresponsive to opioid therapy.
📌 SSRIs significantly reduced pain and depression in fibromyalgia compared to placebo, but showed no significant advantage over non-pharmacological interventions including acupuncture for treating depression.
📌 Left-sided auricular vagus nerve stimulation reduced pro-inflammatory cytokines and increased anti-inflammatory markers and BDNF in women with fibromyalgia, despite not producing superior pain relief compared to sham treatment.